Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share acquisition transactions executed on April 18, 2017, on the London Stock Exchange.
| Transaction Date | Instrument | Price per Share | Total Volume | Nature of Transaction |
|---|---|---|---|---|
| April 18, 2017 | Ordinary Shares (25p each) | £16.4269 | 974 shares | Acquisition via dividend reinvestment |
Breakdown of Transactions:
- Mrs V A Whyte (Company Secretary): Acquired 108 shares.
- Mrs D Connor (PCA of Mr R G Connor): Acquired 279 shares.
- Mr I W Whyte (PCA of Mrs V A Whyte): Acquired 587 shares.
Material Changes
The filing does not provide comparative financial data or material changes to the company's operational performance versus prior periods. The only change reported is the increase in shareholdings for the named individuals due to the reinvestment of dividends paid on April 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific insider trading activity compliant with reporting rules.
Investor Verification Points
- Verify that the share acquisitions were strictly for dividend reinvestment purposes as stated.
- Confirm the transaction price of £16.4269 aligns with the market price on April 18, 2017.
- Note that this filing does not reflect the company's broader financial health or strategic outlook.